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resumo 
 
 
O presente relatório relata a minha experiência de 9 meses enquanto 
estagiária da Eurotrials, Consultores Científicos, uma empresa privada 
especializada em investigação clínica e consultoria científica na área da saúde.  
O estágio insere-se nas atividades curriculares do segundo ano do Mestrado 
em Biomedicina Farmacêutica da Universidade de Aveiro e teve como principal 
objetivo promover a “ponte” entre os conhecimentos adquiridos durante o 
primeiro ano do Mestrado, e o mercado de trabalho, pretendendo servir 
também como meio de aquisição de novas competências, ao permitir a 
integração em algumas das atividades desenvolvidas pela Eurotrials. Ao 
efetuar o estágio no departamento de Epidemiologia & Late Phase research, 
como monitora, o objetivo foi, também, preparar-me, em específico, para 
trabalhar na área da monitorização de estudos observacionais/não-
interventivos. 
Assim, o presente trabalho relata as diversas atividades desenvolvidas numa 
empresa de prestação de serviços na área da investigação clínica e, 
especificamente descrever as atividades de monitorização de estudos 
observacionais/não-interventivos, desenvolvidas durante o estágio.  
Este estágio proporcionou uma visão clara e abrangente das atividades 
desenvolvidas pelas Contract Research Organizations (CROs), e dos 
monitores do departamento de Epidemiologia & Late Phase research em 
especifico e, permitiu pôr em prática os conhecimentos adquiridos ao longo do 
Mestrado bem como adquirir novos conhecimentos.  
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abstract 
 
This report describes my experience of 9 months as trainee at Eurotrials, 
Scientific Consultants, a private owned company specialized in clinical 
research and scientific consultancy in the health area. 
This internship occurred during the second year of master’s degree programme 
in Pharmaceutical Medicine at the University of Aveiro and had the objective 
promoting the "bridge" between the knowledge acquired during the first year of 
the master’s degree and the labour market, and also as a mean to acquire new 
skills by allowing integration in some of the activities developed by Eurotrials. 
Performing the internship in the Epidemiology & Late Phase Research 
department, as monitor, the goal was also to prepare myself, in particular, to 
work in the area of monitoring of observational/ non-interventional studies. 
Thus, this report proposes to disclose several activities developed in a 
company which provides services in the field of clinical research and 
specifically describing the activities of monitoring observational/ non-
interventional studies, developed during the internship. 
This internship has provided a clear and comprehensive overview of the 
activities carried out by Contract Research Organizations (CROs) and their 
monitors and allowed me to put into practice the knowledge acquired during the 
master’s degree and also acquire new knowledge. 
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1. Introduction 
 
In the scope of the second year of the Master in Pharmaceutical Medicine, I had the 
opportunity to carry out an internship. This internship carried out from September 2011 to July 
2012, in the department of Epidemiology & Late Phase Research, of Eurotrials, Scientific 
Consultants. 
 
1.1 Objectives 
 
The main objective of the internship in the department of Epidemiology & Late Phase 
Research, of Eurotrials, Scientific Consultants is to promote the "bridge” between the knowledge 
acquired during the first year of the Master’s degree, and the labour market. By allowing 
integration of some activities undertaken by Eurotrials, it also intended to serve as a mean to 
acquire new skills in a specific area (non-interventional studies) and prepare myself to work in this 
area. 
 
1.2 Structure of internship report 
 
This report is intended to describe the experience acquired and activities performed during 
the internship of 9 months under the supervision of Dr. Maria João Salgado, Executive Director of 
Eurotrials, Scientific Consultants, as well as identify the rationale for conducting 
observational/non interventional studies, characterize the role of the CROs, characterize the host 
company and describe the activities and experience acquired during the internship. Taking this 
into account, this report is divided into six chapters, as follows: 
 
 Chapter 1 – Introduction: This chapter describes the main goals of the internship 
and the organization of the present report; 
 
 Chapter 2 – Overview of observational studies: This chapter describes the state of 
the art of pharmaceutical industry and identifies the rationale for conducting 
observational/non-interventional studies. Observational studies are presented and 
described, and a comparison is made between clinical trials and observational 
studies;  
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 Chapter 3 – Overview of the host company - Eurotrials, Scientific Consultants: This 
chapter identifies some challenges faced, now-a-days, by pharmaceutical industries 
and the role of CROs. It also describes Eurotrials company. For this, is made a 
presentation of the company, its organization, the activities performed, as well as its 
certifications. Similarly, in subchapter 3.3 and 3.3.1, is made a presentation of the 
Epidemiology & Late Phase Research department (department´s presentation: type 
of activities performed, organization, among others), and a characterization of the 
studies developed in this department and also the type of sponsors/ partners 
involved and with what objectives; 
 
 Chapter 4 – Description of ongoing studies and activities performed during the 
internship: This chapter begins with the identification of the type of studies in which 
I was involved and with the identification of some differences between them. After 
this, and throughout this chapter, are also contextualized and described the main 
activities carried out during the 9 months of internship;  
 
 Chapters 5 – Discussion: This chapters aim to give an overview of the internship, 
especially regarding the experience acquired; 
 
 Chapter 6 – Conclusion: In this chapter I present a conclusion about the performed 
internship. 
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2. Overview of observational/non-interventional studies 
 
2.1 State of the art 
 
Currently, pharmaceutical industry continues to have a very important role for European 
competitiveness. In 2011, Europe remained the second largest market for pharmaceutical sales 
and, the pharmaceutical industry was one of the few sectors to contribute positively to the trade 
balance of the European Union (EU), with a trade surplus of €48,3 billion (the largest among of 
the high-tech industries) (1). The pharmaceutical industry also plays a key role in the national 
economy and is considered a strategic sector for Portugal (2, 3). However, we are witnessing a 
major shift in society's expectations in relation to medicinal products, particularly regarding the 
ratio of risk/ benefit and cost/ benefit. The expectation increases due to the recent technological 
development and ongoing level of various technologies that may result in numerous new 
diagnostic and therapeutic methods (4). It is known that in the last decade there has been an 
enormous advance in the basic sciences and technologies as genomics, proteomics, 
metabolomics, bioinformatics and imaging. Nevertheless, despite the increase of scientific 
knowledge and the increase of direct investment in Research and Development (R&D) of drugs, 
the number of new drugs decreased (productivity gap) (5).  
In addition to the difficulty of producing drugs that are innovative, development times are 
extremely long and the failure rates are very high (this is called attrition rate), since the success 
rate is only about 11% which means that if 100 drugs begin to phase I, only approximately 11 is 
going to complete the clinical development phase and be approved. This leads to an 
unsustainable situation of cost of R&D of a new drug have reached values close to €1 billion (see 
figure 1) (6).  
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Figure 1: Clinical development phase: long development times and high failure rates (6) 
  
For the current difficulties in developing new drugs can be overcome, it will become essential 
to implement a new model which adopts new technologies to improve the understanding of the 
disease, reduce costs and increase R&D productivity. It is also important to start working much 
more closely with governments, regulatory agencies and medical community, to produce new 
drugs that patients really need and test them, in humans, as quickly and efficiently as possible. In 
this sense, the current model of development, with its four distinct phases of clinical testing, will 
gradually evolve into a process that is more flexible, integrates and more receptive to rapid 
feedback from patients and providers: The “live-licensing & in-life testing” model (7). 
With the “live-licensing & in-life testing” model,  companies will perform a series of studies to 
ensure a full understanding of efficacy and safety profile of the product, before submitting the 
data to the relevant regulatory agency. Once there is sufficient evidence to show that a medicine 
works and it is cost-effective in the initial trial population, the regulatory agency will issue a "live 
license" that will allows the company to market the medicine on a restricted basis (conditional 
approval) and conduct in-life testing of that medicine. With each incremental increase in evidence 
of safety, efficacy and value, the regulatory agency will extend the obtained license to cover 
different and more patients or multiple indications (see figure 2) (7, 8).  
 
Figure 2: Actual model versus “Live-licensing & in-life testing” model (6) 
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This new model has several advantages (for example allows reducing clinical development 
costs and aligning the bench and the bedside more closely) but will have the inevitable 
consequence of the need to continue studying the medicine after their marketing introduction. 
Therefore, the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) 
will place more emphasis on post-marketing surveillance studies, and all of this will lead to an 
increase necessity to perform observational/non-interventional studies for obtain evidence that 
new medicines are safe and effective, in different patients population, and also that are better 
than others comparable therapies (7, 9). 
 
2.2 Overview of observational/non-interventional studies  
 
In the last half century there have been many medical advances, verified in world population, 
that enabled the emergence of new medicines, vaccines and other medical tools that contributed 
to extraordinary gains in terms of health. The effective use of new medicines has led to increased 
longevity and improved the quality life of patients. The emergence of new medicines also allowed 
obtaining important social and economic benefits for patients, and even for the economy in 
general (10). 
It is known that the discovery of new medicines is governed by strict principles of 
organization and planning of the research methodology. The development of new molecule 
includes, as a first stage, a thorough evaluation by laboratory tests, which permits extrapolation 
of results in the absence of evidence of potential toxicity problems. There is a phase of 
exploratory tests (exploratory development) and the first exposure in humans (first in man). The 
next stage (full development) requires the conduct of clinical trials, which includes the classic 
phases (phases I to III) essential for the initial approval of the drug by the competent authorities. 
Clinical trials are the universally accepted method for research (11).  
According to the Guideline of Good Clinical Practices E6(R1), a clinical trial is defined as “Any 
investigation in human subjects intended to discover or verify the clinical, pharmacological and/or 
other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse 
reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, 
and excretion of an investigational product(s) with the object of ascertaining its safety and/or 
efficacy”. The terms clinical trial and clinical study are synonymous (12).  
In this way, it is easily understood the need of having a very tight regulation and with high 
complexity of scientific, ethical and legal level. Therefore, between the laws and regulations 
applied to this area, stand out the followings (13): 
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 Declaration of Helsinki (2008 version) - definition of ethical principles for medical research 
involving human subjects (14); 
 ICH GCP E6(R1), Good Clinical Practices - an international standard for the conduct and 
reporting of clinical trials (12); 
 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 - 
provides the requirements for the conduct of clinical trials in the EU. The scope is about 
the approximation of the laws, regulations and administrative provisions of the Member 
States relating to the implementation of good clinical practice in the conduct of clinical 
trials on medicinal products for human use (15); 
 Directive 2005/28/EC of 8 April 2005 - established principles and detailed guidelines for 
good clinical practice as regards investigational medicinal products for human use, as well 
as the requirements for authorization of the manufacturing or importation of such 
products. Concretizes the clinical trials directive (16).  
 
National Law: 
 Law no 46/2004 of 19 August - transposition of Directive 2001/20/CE. Approving the legal 
regime for the conduct of clinical trials with medicinal products for human use (17);  
 Law no 67/98 of 26 October - protection of personal data (18); 
 Decree-law no 102/2007 of 2 April - transposition of Directive 2005/28/CE. Established 
the principles and guidelines of good clinical practice in regards to the investigational 
medicinal products for human use, as well as the special requirements for manufacturing 
authorization or import of these products (19). 
 
The main objective of the above mentioned legislation is to have common rules in the clinical 
research area and to ensure that the human dignity and fundamental rights of the participants in 
the studies are respected. 
Clinical trials are highly legislated and provide evidence of efficacy and safety of new drugs in 
a limited set of patients with particular clinical situations and for limited periods of time, essential 
for obtaining marketing authorization of these new drugs. However, observational studies are 
more suitable to detect rare or late adverse effects of treatments and, currently there is a 
growing need and importance of collecting data in "real life" in order to  provide data for the 
different stakeholders (pharmaceutical industry, health authorities, payers, patients) on the 
effectiveness and safety of drugs in "real life" as well as the consumption of health care resources 
associated to the introduction of new therapies (20).  
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Increasingly, there is recognition of the role played by data about patients’ use in normal 
clinical practice or in settings better reflecting the reality of health care delivery. The collection 
and use of “real world” data1 can enable all parties to achieve their objectives and, ultimately, to 
maximize patients’ health gains given the limited National Health Service (NHS) resources (21). 
Having said this, it becomes necessary to perform another type of studies to obtain more data 
about the “real life". Thus, in order to bridge the limitations of data obtained by clinical trials 
(from a limited set of patients with particular clinical situations and for limited periods of time), it 
is necessary to carry out observational/non-interventional studies, in an environment of normal 
clinical practice, with a larger, and more diversified, population.  
Observational studies are epidemiological/ non-experimental studies that do not involve 
intervention (22). According to Article 21 of Directive 2001/20/EC, a non-interventional trial is 
defined as: “a study where the medicinal product(s) is (are) prescribed in the usual manner in 
accordance with the terms of the marketing authorization. The assignment of the patient to a 
particular therapeutic strategy is not decided in advance by a trial protocol but falls within current 
practice and the prescription of the medicine is clearly separated from the decision to include the 
patient in the study. No additional diagnostic or monitoring procedures shall be applied to the 
patients and epidemiological methods shall be used for the analysis of collected data” (15). 
Taking this into account, it is important to note the existence of observational studies 
conducted with drugs according to the marketing authorization who follow clinical practice, 
without additional procedures (pharmacoepidemiological studies) and also the existence of 
observational studies without drugs, such as disease/patients registry studies, genetic 
characterization of diseases among others. 
Another of the aspects that differentiate clinical trials and observational/non-interventional 
studies is the almost complete lack of regulation of the latter, with except the existence of the 
Eudralex vol 9A - 2007 legislation for post-authorization safety studies (PASS studies, which aims 
to identify and/or characterize a safety problem concerning an approved drug) (23). However, 
there are some guidelines that should be followed when designing, conducting and reporting non-
interventional studies, namely: 
 Good Epidemiological Practices (GEP) 2007 - guidelines for proper conduct in 
epidemiologic research. The aim is to provide a set of guidelines for the conduct of high 
quality epidemiological research and proper collegiate behavior (24); 
                                                          
1 Real world data has been defined by an International Task Force as data used for clinical, coverage, and 
payment decision-making that are not collected in conventional randomized controlled trials. Real world 
data describes what is really happening in everyday normal clinical healthcare practice. This can include 
data from existing secondary sources and the collection of new data, both retrospectively and 
prospectively. 
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 Good Pharmacoepidemiological Practices (GPP) 2007 - intended to propose minimum 
practices and procedures that should be considered to help ensure quality and integrity 
of pharmacoepidemiologic research, and to provide adequate documentation of research 
methods and results (25); 
 Volume 9A (Rules Governing Medicinal Products in the European Union) - guidelines on 
pharmacovigilance for Medicinal Products for Human use. Intended to provide general 
guidance on the requirements, procedures, roles and activities in this field, for both 
marketing authorization holders and Competent Authorities of medicinal products for 
human use; it incorporates international agreements reached within the framework of 
the International Conference on Harmonization (ICH) (23); 
 AHRQ (Registries for Evaluating Patient Outcomes) - intended to support the design, 
implementation, analysis, interpretation, and quality evaluation of registries created to 
increase understanding of patient outcomes2 (26); 
 STROBE (Strengthening the reporting of observational studies in epidemiology) 
Guidelines - to provide guidance on reporting the observational studies results. For this, 
was developed a checklist of 22 items essentials to improve reporting quality (27). 
 
Nevertheless it is being made an effort on standards creation to perform a better non-
interventional pharmacoepidemiological research. An important advance in this sense, was the 
EMA initiative in establishing the European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCePP).    
The main objective of this network is enable the acess to a robust network of resources for 
improve risk-benefit monitoring, pharmacoepidemiological research and post-authorization 
safety surveillance of medicines across Europe, based on principles of transparency and scientific 
independence (28). As example of ENCePP resources we can have (29): 
 ENCePP code of conduct - which objective is to provide a set of rules and principles 
for the conduct of pharmacoepidemiology and pharmacovigilance studies (30);  
 ENCePP checklist for study protocols - intended to promote the quality of studies by 
stimulating the consideration of important epidemiological principles to design a 
pharmacoepidemiological or pharmacovigilance study performed in the EU and for 
writing a study protocol (31); 
                                                          
2
 A patient registry is an organized system that uses observational study methods to collect uniform data 
(clinical and other) to evaluate specified outcomes for a population defined by a particular disease, 
condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A 
registry database is a file (or files) derived from the registry. 
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 ENCePP guide on methodological standards in pharmacoepidemiology - gives an 
overview of the internationally acknowledge recommendations with the final 
objective to assure quality in the studies performed by the European network (32); 
 ENCePP database of research resources - an electronic database that comprises two 
Indices: the Inventory of ENCePP research centres and the registry of EU data 
sources, and  offers information in the available sources of expertise and research 
experience, in the field of pharmacoepidemiology and pharmacovigilance, across 
Europe (33). 
In the Inventory of ENCePP research centres it is possible to identify that, there are seven 
Portuguese ENCePP centres registered, which includes Eurotrials. 
On the other hand, among European countries, it’s also noted that, despite the different 
requirements regarding the approval by Ethics Committees and different procedures for the 
informed consent (depending on the study design), most of the countries have legislation 
regarding protection of personal data. In Portugal, in particular, the deliberation of the National 
Commission for Data Protection (CNPD), applicable to this type of study, is the CNPD Deliberation 
No. 227/2007. The applicable CNPD Law is No. 67/98. 
In summary, epidemiological or observational/non-interventional studies, unlike clinical trials 
do not involve active intervention (34).  The observational studies are mainly focused in studing 
the effectiveness (eficacy in the real world), they study a wide and unrestricted population, do not 
required an intense ICH-GCP compliant monitoring and are less expensive when compared with 
clinical trials (see table 1). 
 
Table 1: Summary of differences between randomized controlled trials and real world studies (21) 
 
 Randomized Clinical Trials Real World Studies 
Type of Trial Experimental / interventional Observational/ non-interventional 
Primary focus Efficacy, safety and quality Effectiveness 
Patient population Narrow and restricted Wide and unrestricted 
Monitoring Intense (ICH-GCP compliant) None / standard clinical practice 
Cost More expensive Less expensive 
 
Taking all this into account, it is possible to understand the importance of performing clinical 
trials in order to provide evidence of efficacy and safety of new drugs (in a limited set of patients 
with particular clinical situations and for limited periods of time), essential for obtaining 
marketing authorization of these new drugs, and also the importance of performing 
observational/non-interventional studies in order to  provide data for the different stakeholders 
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(pharmaceutical industry, health authorities, payers, patients) on the effectiveness and safety of 
drugs in "real life" as well as the consumption of health care resources associated to the 
introduction of new therapies (see figure 3). 
 
 
Figure 3: Clinical trials and Late phase studies (35) 
 
Regarding the epidemiological studies the historical context of epidemiology and its 
contributions to health promotion and disease prevention, justified its recognition as essential in 
the global strategy for health, for all by the World Health Assembly in May of 1988 (36). 
Epidemiology is a basic science and clinical medicine, fundamental to characterize health 
problems, from initial diagnosis to its control, therefore the study target is human population and, 
according to the Last (1998) definition, the scope of epidemiology is "the study of distribution and 
determinants of health conditions or events associated with them, in specific populations and the 
application of this study to control health problems” (37). Thus, epidemiology is not only related 
with death, illness or disability, but also with more positive health states and which means to 
improve health. So, in recent years the value of information about disease distribution for 
planning the delivery of health care has become more evident and there is also an increasing 
interest in studying the effectiveness of the health-care system and/or of different treatments 
(38). 
In what concerns to clinical epidemiology, the methods may be applied to answer the clinical 
questions, useful in patient care, namely: etiology, diagnosis, prognosis, treatment, prevention, 
evaluation of health care services and analysis of risks and benefits, and for this, there can be 
used different designs and types of studies (36).  
However this situation should be well analysed because the choice of an appropriate study design 
is a crucial factor in conducting observational/epidemiological studies. Still, we can say that design 
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is no better or worse than the other, it may be more or less appropriate depending on the study 
question and the general circumstances involved (39, 40).  
In the following figure it is possible to observe different types of study designs and associated 
features:  
 
Figure 4: Epidemiological studies: designs and characteristics (41) 
 
Regarding to the designs it is important to highlight that the studies can be carried out by 
retrospective or prospective data collection. A prospective study is an observational study, often 
longitudinal in nature, for which the consequential outcomes of interest occur after study 
commencement. On the other hand, a retrospective observational study employs existing 
secondary data sources in which both exposure and outcomes have already occurred (42). So, for 
choosing the appropriate methodology, there are some factors to consider (see table 2): 
  
Study design 
Interventional Longitudinal Prospective   - Clinical Trial 
Non-Interventional/ 
epidemiological 
Longitudinal 
Prospective  
(cohort) 
  - Investigation 
  - Disease Incidence 
  - Observation of the             
standards of treatment 
Retrospective  
(case-control) 
 Comparing cases with 
controls with regard to 
exposure to drugs  
Transversal ___ 
  - Studies of disease 
prevalence 
  - Studies of characterization 
of disease / treatment 
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Table 2: Prospective and retrospective designs - applications, vantages and limitations (21) 
 
 
 Prospective Retrospective 
Scope of dataset Can include data not routinely recorded 
e.g. formal disease rating scales, 
Patient Reported Outcomes 
Data reflects current treatment 
Can only include routinely recorded data 
Need to balance need for current data 
vs. eligibility period need to obtain 
enough patients vs. number of sites  
Timelines Depend on rate of presentation of 
suitable patients 
Predictable, short data collection period 
Patient consent Easy to seek as patient present to clinic Can be more difficult to obtain 
 
As a example of the studies with these designs, we can have, not only but also the followings 
(21): 
 Retrospective design: 
 Retrospective chart review; 
 Primary care database study; 
 Secondary care database study; 
 Case-control study; 
 Cohort study. 
 
 Prospective design: 
 Cohort study; 
 Prospective outcomes study; 
 National registry; 
 Patient reported outcomes3 study (21, 43); 
 Post marketing surveillance/safety study. 
 
Among the epidemiological/ observational studies, stand out the cohort studies and case-
control studies. They have some similarity with experimental studies, namely two groups, one of 
which is the control group. However, they are not experimental since there do not have 
randomizations or manipulation of exposure. 
                                                          
3
 Patient-Reported Outcomes (PROs) are reports coming directly from patients about how they feel or 
function in relation to a health condition and its therapy without interpretation by healthcare professionals 
or anyone else. These survey instruments provide an important and highly relevant way of assessing the 
effects of treatment, which are complementary to conventional clinical endpoints. 
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In cohort studies are formed groups of exposed and unexposed and they are followed for 
some time in order to determine the occurrence of the disease in focus and the relation with the 
exposure of interest (see figure 5). These studies can be prospective or retrospective (40, 44).  
 
 
 
Figure 5: Cohort Studies (37) 
 
On the other hand, case-control studies compares prevalence of risk factors in a sample of 
individuals with the disease (cases) and the prevalence in a sample of individuals without the 
disease (controls) and, after, looks to the past (retrospective design) to identify differences that 
may explain the reason for cases developing the disease cases and controls did not (see figure 6) 
(40, 45).  
 
 
 
Figure 6: Case-control study design (37) 
 
Moreover, there are also cross-selection studies, also known as prevalence studies, which 
determine the distribution of health states and their determinants, in a population at a particular 
moment in time (see figure 7). In this studies, the measurements of exposure and effect are made 
at the same time (37, 44). 
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Figure 7: Cross-selection study design (adapted from reference (39)) 
  
With disease and with 
exposure 
 Population Sample 
Prevalence 
of disease in 
exposed 
Prevalence of 
disease in 
unexposed 
Without disease but 
with exposure 
With disease but 
without exposure 
Without disease and 
without exposure 
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3. Overview of the host company - Eurotrials, Scientific 
Consultants 
 
3.1 Overview of Contract Research Organizations 
 
Throughout the history of pharmaceutical industry, big companies have always tried to carry 
out all stages of R&D internally, with infrastructure and its own staff (46). However, the increasing 
pressure on the global pharmaceutical industry costs, due to declining productivity of R&D, longer 
R&D timelines and increased costs to develop new medicines and for legislative requirements, has 
led to the increase of outsourcing of some stages of the process of R&D (46). 
The research or study is then possible to be performed not only through internal resources (in-
source), as well as through to external resources (outsource), that occurs when pharmaceutical 
companies contract third parties to conduct their studies (47). So, the outsourcing can be 
contracted locally or at a global level. Regarding advantages and disadvantages of this, it is 
possible to say that internal resources have as advantages the relationship that is established 
between researchers and Key Opinion Leaders (KOLs), competitive intelligence, business culture, 
higher availability, the first contact to new therapeutic areas and synergies with other structures 
of the company. However, on the other hand, these resources have also disadvantages, such as, 
the need for greater investment in education and training, and the existence of a heavier 
structure (48). Thus, the increasing cost pressure on the global pharmaceutical industry and the 
increasing pressure to bring more new drugs to the market while at the same time they have to 
cut their R&D budgets, has led, increasingly, the companies to search for outsourcing their R&D to 
Contract Research Organizations (CROs) (see figure 8) (47).  
 
 
Figure 8: Estimated CRO total market revenues, 2000-2010 (49) 
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The CROs offers many services that the pharmaceutical industry do not have or are not 
willing to maintain in its organizational structure, namely: 
 Medical writing; 
 Regulatory support; 
 Centre/Investigator selection and qualification; 
 Study management and monitoring; 
 Pharmacovigilance; 
 Drug management; 
 Data processing; 
 Data analysis (biostatistics). 
The CROs services can help to alleviate the constraints verified at pharmaceutical industry level 
and can increase R&D effectiveness and at lower costs (48). In the same way, the CROs services 
can representing a greater structural flexibility, greater sense of urgency and also the existence of 
immediate resources that can fill gaps in the areas of competence (50). However, despite sponsor 
can outsource their R&D to the CRO, during the course of the study or before the start of it, and 
may transfer some or all of its obligations and functions related to the study, it should be noted 
that the last responsibility for the quality and integrity of the data will be of the sponsor.  
CROs have the capability to design, implement, conduct, collect and process data from 
clinical trials and observational/non-interventional studies, leaving the pharmaceutical industry to 
define the role of development strategy (clinical trials) and maintenance lifecycle of their products 
(observational/non-interventional studies). 
In Portugal, in accordance with the world situation, there is a growing pressure on the 
pharmaceutical industry in order to ensure that the cost and the time to market of new products 
are reduced. This pressure leads to that, in Portugal, there is also an increase of the search for the 
CROs services, opting for lighter and more flexible structures (48). There are several such 
organizations but one that stand out is the Eurotrials, Scientific Consultants, a CRO specializing in 
clinical research and scientific advice in health sciences. 
 
3.2 Overview of the host company - Eurotrials, Scientific Consultants 
 
My internship took place at Eurotrials, Scientific Consultants, a privately owned company 
founded in Lisbon in 1995 by members of academia, medical community and pharmaceutical 
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industry, that operates in Europe and Latin America (Brazil, Argentina and, more recently, in Chile) 
(51). 
Eurotrials have expertise on clinical research and scientific consulting in health sciences and 
is committed to provide quality and efficiency services at international level, in the optimization 
of existing research centres and in the development of research centres of high potential, training 
and motivating new human resources in clinical research and in establishing strategic 
partnerships which includes pharmaceutical industry, healthcare institutes and medical societies 
and associations (see table 3)  (52): 
 
Table 3: Eurotrials partners 
 
Eurotrials partners 
Pharmaceutical industry Consultancy firms 
Biotechnology companies Institutions: health and others 
Medical devices and diagnostics companies Health regulatory authorities 
Hospitals and clinical research centres Foundations 
Research sites networks Corporate technology centres and business 
associations 
Medical societies and associations IT companies 
Research institutes Financial groups 
Others CROs Food sector companies 
Healthcare professionals Medical hydrology companies 
Patient associations Cosmetic companies 
 
Eurotrials is proposed to undertake the production of science and technology able to 
compete nationally and internationally and is recognized and certified by different entities:  
 ISO certification - ISO 9001 quality certification from Lloyd\'s Register Quality Assurance 
with UKAS (UK Accreditation Service). After that, in 2002, Eurotrials had another step in 
the consolidation and guarantee of this work philosophy, with a transition to ISO 
9001:2000. In 2009, Eurotrials accomplished the transition of the certification to ISO 
9001:2008 (53). 
 “Rede PME Inovação COTEC” - an initiative designed to promote public recognition of a 
group of Small and Medium-sized Enterprises (SMEs) whose innovative attitude and 
activities make them an example of creation of value for the country (53). 
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 Leading SME - that recognized Eurotrials as a leading SME because was considered by the 
organization as a driving force in the national economy, due to the quality of their 
performance and their risk profile (53). 
 
Eurotrials is qualified to participate in all the steps of any clinical, translational or 
epidemiological research project, from the initial research question to the availability final results 
or final publication. So, in order to be able to perform its services and activities, Eurotrials is 
organized in the following departments, which communicate and interact with each other (see 
figure 9) (54):  
 
 
Figure 9: Eurotrials Portugal organizational chart (54) 
 
3.3 Overview of Epidemiology & Late Phase Research department 
 
Epidemiological studies and Late Phase Research studies were initially conducted by the 
clinical trials department, the largest department and the first to be created in the Eurotrials 
however, due to the growth of this type of studies, was created, in 2000, a independent 
department to carry out the activities related to non-interventional studies the Epidemiology & 
Late Phase Research department. 
Although this department is still quite small when compared with the clinical trials 
department, it has already, a diversified constitution, that can be justified by the great diversity of 
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services performed that can go from the study design, conception of the project (protocol 
development, as well as patient information and informed consent forms, case report form, etc.) 
until the publication of scientific results. In this way, the employees of this department are 
involved in different type of activities, in close collaboration with the other departments from the 
company, such as: 
 Conception and methodological design of studies; 
 Development of study protocol, as well as other documents such as patient information 
and informed consent forms, case report forms, questionnaires, diaries, specific forms of 
study, and others (as applicable); 
 Study submission to health authorities  (CNPD, Ethics Committees, Administration Boards, 
among others, depending on the study), and subsequent interaction with health 
authorities; 
 Centralized project management; 
 Development of tools for managing the studies conduction; 
 Studies conduction (initiation visits, training sessions, monitoring visits, quality control 
visits, close out visits, among others); 
 Implementation of in-house monitoring activities; 
 Contact and support to study investigators or other elements involved; 
 Training of investigators/ inquirers/  sponsor teams; 
 Surveys execution (street/phone); 
 Bibliographic searches; 
 Preparation of multimedia presentations;  
 Preparation of final report/ scientific articles/ posters. 
There are different goals for conducting non-interventional studies, but the majority are related 
to  (55): 
 Generation of clinical effectiveness data; 
 Support & strengthen the product safety profile; 
 Provide “real-world” clinical and economic outcomes; 
 Support the development of “best-practice” guidelines, and standards of care; 
 Create value for new therapies; 
 Support the strategy for hospital access; 
 Use objective data to drive product lifecycle planning; 
 Maximize communication opportunities with key customers; 
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 Promote disease awareness; 
 Collect diseases prevalence and incidence data; 
 Knowledge about the clinical practice; 
 Gather information on the management of diseases and use of medication; 
 Knowledge of the burden/ impact of disease. 
 
Currently, the Epidemiology & Late Phase Research department relies with the collaboration 
of 8 persons, including a head of the department, a project manager, a senior monitor (also called 
as Clinical Research Associate, or CRA), four monitors/CRAs, and a Clinical Trials Assistant (also 
called as CTA) which gives administrative support to CRAs, (see figure 10 where is represented, 
schematically, the organization of department). 
 
 
 
Figure 10: Epidemiology & Late Phase Research department organogram 
 
Eurotrials develops and conducts different type of studies and the majorities are the 
Community Based studies, followed by Clinical Practice Characterization studies and 
Pharmacoepidemiological studies (see figure 11).  
 
Head of Department 
Senior CRA 
CRA CRA 
CTA 
CRA CRA 
Project 
Manager 
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Figure 11: Type of studies developed by Epidemiology & Late Phase Research department (56) 
 
However, in the last years the Health Economic Outcomes studies are growing mainly due to 
the health authorities and payers request of evidence of the clinical, economic and humanistic 
outcomes associated with the market drugs. 
These studies can take place in some different kinds of institutions, such as: public and 
private hospitals/ clinics, primary healthcare centres, other health institutions (for example, 
medical private offices). Nevertheless, it is important to describe what are the main objectives 
intended to be achieved with these studies, as well as the type of partners of Eurotrials/ the main 
type of sponsors. 
 
3.3.1 Characterization of the type of studies conducted and the main partners involved 
In the Epidemiology & Late Phase Research department are carried out basically 
epidemiological studies and Late Phase studies, with differents partners/sponsors (see figure 12). 
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Figure 12: Type of studies and main partners of Epidemiology & 
Late Phase Research department (55) 
 
The epidemiological studies, as mentioned above, are fundamental to characterize health 
problems, from initial diagnosis to their control. In this sense, and due to the lack of 
epidemiological information on a national level for some diseases, it is essential and appropriate 
the implementation of studies that estimate the incidence4 of diseases in the Portuguese 
population and that characterize other aspects relating to their epidemiology, diagnosis and 
treatment. So, at Eurotrials, this kind of studies are often performed in this department and the 
sponsors are, usually, primarily the medical scientific societies, medical community, patients 
organizations, government agencies, regulatory agency with diverse goals such as: to know the 
prevalence5 and incidence of diseases, characterize specific populations, characterize the clinical 
practice for certain pathologies and measure and evaluate the Public Health measures (37, 57, 58).   
On the other hand, in the Epidemiology & Late Phase Research department of Eurotrials are 
also developed Late Phase studies.  
Late Phase studies are a major driving force behind the development of (new) medicines. 
They can target particular therapeutic areas or populations where relevant clinical data are 
required to ascertain the effectiveness, safety, acceptability, utilization patterns and cost-
                                                          
4
 The incidence of a disease is the rate at which new cases occur in a population during a specified period. 
5
 The prevalence of a disease is the proportion of a population that is affected by the disease at a specific 
time. 
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effectiveness of a product. The existence/availability of epidemiological and post-
commercialization studies data are crucial in validating scientific therapeutic, economic and 
healthcare policy solutions (55). Therefore, these studies are mostly sponsored by the 
pharmaceutical industry and/or by regulatory agencies and they are very important, in particular, 
for completing the information obtained in clinical trials, in the previous phases, after obtaining 
marketing authorization, in order to allow data collection in a "real population". Thus, these 
studies contribute to the main objective of safety monitoring in a real clinical setting  in a large 
population, they also contribute to assess whether the drug brings, or not, an additional burden 
to the health care system, in terms of resource utilization and also if it improves the patients 
quality of life. 
In this way, these kind of studies are particularly important, for example, for the following 
cases: 
 To study the clinical "outcomes" in a diversified population, that reflect clinical practice 
- effectiveness studies; 
 To make comparison between several alternative interventions in the "real" 
population; 
 To study the compliance and the Quality of Life of patients (QoL) in a real 
environment; 
 To Collect data usage (data about the consumption of resources in a pathology for 
assignment of costs and economic evaluations - pharmacoeconomic studies) (59); 
 To obtain information on how a product and/or therapeutic strategy is used in clinical 
practice – characterization of clinical practice; 
 To study special populations that are not subjected to clinical trials (eg, pregnant 
women, children); 
 To answer the need and obligation to collect safety data for new drugs after the 
placing on the market - PASS studies. 
 
Here it should be noted the last point, relating to the need and obligation to collect safety data on 
new drugs because, in fact, such studies may be required by regulatory authorities when there 
are a “conditional” drug approval, having as a main objectives the identification of security 
aspects that may not yet be known, the investigation of the risks already flagged and potential 
new risks, in order to assess the possible causal associations; confirmation of the safety profile of 
the drug in "real conditions" and the quantification of unknown, and know, adverse reactions and 
finally the identification of possible risk factors for certain adverse reactions (60). Indeed 
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according to the Directive 2010/84/EU, a post-authorization safety study is “any study relating to 
an authorized medicinal product conducted with the aim of identifying, characterizing or 
quantifying a safety hazard, confirming the safety profile of the medicinal product, or of 
measuring the effectiveness of risk management measures” (61). 
Thus, when we think about potential partners/sponsors of the Late Phase studies, we may 
have the regulatory authorities, the pharmaceutical industry, and even the governmental entities, 
the medical community and the patients associations (see table 4). 
 
Table 4: Type of partners/sponsors of Late Phase studies and objectives (62) 
 
Types of sponsors/ partners Objectives 
 
 
Regulatory authorities 
To collect of safety data after MA 
To study the effectiveness and resource consumption  
To compare the cost-benefit of therapeutic alternatives 
to market entry decision and to the reimbursement 
process   
To study populations that are not included on the 
clinical trials (special populations)  
 
 
 
Pharmaceutical industry 
To obtain information of the use of a product and/or 
the therapeutic strategy in clinical practice 
To study the clinical outcomes in a diverse population 
that reflect clinical practice 
To study/characterize patients subgroups that respond 
differently to a given therapy 
To study the compliance and the QoL in a real 
environment 
 
Government entities/medical 
community/ patient 
associations 
To know the prevalence and incidence of diseases 
To characterize specific populations 
To characterize the clinical practice for certain 
pathologies (e.g. therapeutic strategies used, degree of 
disease control, among others) 
To study the impact of the disease on the society 
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4. Ongoing studies and developed activities 
 
During the 9 months of internship as CRA trainee of Epidemiology & Late Phase Research 
department, I had the opportunity to participate on a wide variety of studies with different 
regulatory requirements (see Appendix B - Main studies ongoing during the internship). Since the 
different studies are performed in different type of sites (primary care, secondary care, private 
medical offices), I had the oportunity to learn about different requirements for the regulatory 
submissions for the different kind of sites. Throughout this chapter, I will contextualize some of 
the activities performed and describe them. However, I will start by refer some of the types of 
sites in which the Epidemiology & Late Phase Research department has ongoing studies and some 
differences in conducting studies in different kind of “places” (in open streets, medical private 
offices, private clinics, primary healthcare centres and in secundary healthcare centres 
[hospitals]). 
 
4.1 Type of sites of ongoing studies 
 
4.1.1 Ongoing surveys (population surveys) 
One of population survey study in which I was involved was an epidemiological study, 
observational, cross-sectional (see study No. 15 of Appendix B - Main studies ongoing during the 
internship) whose collection of information was made in domiciles, through the direct and 
personal approach made by inquirers, by applying a questionnaire/survey to a population sample 
that was stratified by sex and age group to be a representative sample of the portuguese 
population.  
The data collected in this study was totally anonymous, with no data that could identify 
directly or indirectly the study participants. For this reason, and since the study was totally 
anonimous, no personnel data was collected, so there was no necessity to obtain the CNPD 
approval.  
Also no specific regulatory approval was necessary for the study conduction, since these kind 
of surveys are applied/filled in participants' domiciles. This kind of studies have a fast 
implementation and conduction even when large number of questionnaires have to be obtained, 
because there is no need to wait for any regulatory approval to implement and conduct the study. 
Regarding the activities performed in the conduction of this study, I had the opportunity to 
develop some tasks namely the contacts with the inquirers, the collection, review, tracking, and 
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shipment of the questionnaires to Eurotrials Data Management department of the completed 
obtained questionnaires and the updating and maintenance of the study files. So, this study 
allowed me to acquire and develop other skills, such as understand the dynamics of managing and 
planning the activities of the inquirers and the importance of understanding how the study is 
progressing in order to better plan the next steps, differents those that will be mentioned in the 
hospital based studies. 
Another survey study in what I was also actively involved, was a study that had the objective 
of understanding the portuguese reality concerning the screening, referral and selection of 
antiviral therapy to the patients with chronic hepatitis B  (see study No. 14 of Appendix B - Main 
studies ongoing during the internship). This study was conducted through the application of a 
survey/questionnaire to a sample of physicians with different specialities. This study, was also 
quickly implemented, since there was no individual patient data collection, the study was based in 
the physicians responses to a specific questionnaire, so it was not necessary to obtain any 
regulatory approval for the study conduction in Portugal. Regarding the activities performed, they 
were essentially concerning the invitation to several selected physicians (either by email or by 
phone), the application of the questionnaire by email or phone, giving the necessary support for 
answering questions and finally the creation of strategies for attracting more physicians to 
participate in the survey. I also had the opportunity to register the questionnaire answers into a 
specific database and collaborate in the analysis of the responses.  
 
4.1.2 Ongoing studies in medical private offices 
During the internship period, I was mainly integrated in the studies taking place in hospitals. 
Still, although I had not accompanied the submission phase of some existing studies that took 
place in medical private offices (see studies No. 5 and 9 of Appendix B - Main studies ongoing 
during the internship), I executed some in-house monitoring activities (including revision of Case 
Report Forms [CRFs] to verify the patients eligibility and the, subsequent emission of queries 
resulting from the revision/verification of CRFs). I also had the opportunity to help in the 
preparation of some monitoring visits.  
Comparing the studies that are conducted in private medical offices with the studies that are 
conducted in hospitals (public or private), I could learn that, after activation of the sites, the 
studies are essentially developed in the same way. However, the submission phase is different, 
since in the medical private offices, there is no Ethics Committee (EC) and/or Administration 
Board (AB) to submit the study, so it was possible to understand that, in these kind of sites, the 
studies are more quickly implemented when compared with hospitals that have an local EC/AB, 
where the study as to be submited for approval. 
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4.1.3 Ongoing studies in primary healthcare centres 
Additionally, I also was involved in some activities of an studies conducted in primary 
healthcare centers (see studies No. 7, 8 and 12 of Appendix B - Main studies ongoing during the 
internship). During this study I performed contacts with the local Health Regional Administration 
(ARS) to obtain information concerning the study submission and I also had the opportunity to 
participate with the responsible monitor in a quality control visit done to one of the 
investigational sites.  
This study, allowed me to acquire additional knowledge that until now was not possible. I 
could see that, unlike the private clinics and hospitals, here there is an organization of the primary 
healthcare centers, by region. In other words, while in the studies that claim to be developed in a 
hospital environment, the submission is made to the specific hospital, in the case of primary 
healthcare centers, although generally it is necessary to obtain a authorization from the health 
care center coordinator to authorize the execution of the study, the study must always be 
submited and evaluated by the local ARS (ARS North, Centre, Lisbon and Tagus Valley, Alentejo 
and Algarve, whichever is applicable) depending on the region where the study will take place.  
After obtaining the approval of correspondent local ARS, the study may occur in any primary 
healthcare center in that region (excepting cases where the coordinator of the unit do not 
authorize and cases where the respective Health Centers Group [ACES] to which the unit belongs, 
have something to object). However, it was possible to verify that, despite the existence of an EC 
and a AB, such as in hospitals, the time of approval of the study by ARS may be longer than in 
hospitals.  
Regarding the quality control visit performed, I also had the opportunity to observe that, in 
that specific site (but similar to what may happen in other primary healthcare centers), the 
patient clinical file was in paper and also in a electronic format. This situation represented a 
bottleneck in performing monitoring/quality control activities because the access to the complete 
patient clinical information becomes more complicated. 
 
4.1.4 Ongoing studies in hospitals (public or private) 
As already mentioned, during the 9 months of internship, I was mainly integrated into the 
ongoing studies in hospitals  (see studies No. 1, 2, 3, 4, 6 and 11 of Appendix B - Main studies 
ongoing during the internship). Unlike described for ongoing studies in private offices, here I could 
follow the early stage of some studies in hospitals so, I could have a realistic view regarding the 
procedures for study submissions to the hospitals, as well as to the deadlines for evaluation and 
approval of each site and even the differences from site to site. Concerning the studies that I was 
integrated, it should be noted that I participated in some activities in international studies, 
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however I was mainly involved in national studies, especially in two studies, in neurology area and 
VIH area, where I developed the main activities that will be described further on this internship 
report. 
 
4.2 Developed activities during the internship 
 
4.2.1 Confidentiality agreement 
Before the beginning of any kind of activity, any new collaborator of the Eurotrials starts by 
signing a confidentiality agreement. This process has a particular importance in the organizations 
concerned (CROs) because they work with different sponsors and have access to confidencial 
information that must be safeguarded. After signing the confidentiality agreement, the new 
collaborator will begin to have access to information and is then able to start a new phase: the 
training program.  
 
4.2.2 New employee training program 
This training program has a theoretical and practical approach and has been designed in 
order to train the new collaborator in the activities that he will execute in the future, however the 
training program also includes the reading of documents that are transversal to all of different 
departments. In addition to the general training it should be noted that the training program also 
includes a specific training related to projects/studies in which the collaborator will participate, 
and these training should be performed throughout the collaborators career path (whenever 
applicable). 
 
4.2.2.1 General training program 
The general training program which is carried out by a new collaborator of Eurotrials, 
presupposes the reading of essential documents, necessary to perform the activity, such as:  
 Standard Operations Procedures (SOPs) of the company (including SOPs in which the 
training is required by all colaborators and the SOPs that are only mandatory for some 
collaborators depending of the main activity performed/ department and position. An 
example is the reading of SOP related to site initiation visit that is not mandatory for 
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the Biostatistics department collaborators, but the read of staff training SOP is 
mandatory for everyone); 
 Colaborator’s manual (which seeks to create the best conditions for the integration of 
new colaborator to identify themselves, as soon as possible, with the company's 
culture and be active members of them); 
 Other reference documents (GPP, GEP, Declaration of Helsinki, ICH-GCP, local 
legislation, among others) listed in the matrix of training made available to each 
colaborator. 
 
4.2.2.2 Training program in specific projects  
In addition to the general training in the activities to be performed, it is also essential that 
the new colaborator receives a  training in the project in which he/she  will participate. This kind 
of training includes reading of documentation inherent to the study such as: study protocol, case 
report form, patient information and informed consent form, therapeutic area, among others. 
The collaborator can also perform a specific, additional training, provided by the sponsor of the 
study. 
It should however be noted that, although the training programs are critical at the beginning of 
the activities of the new colaborator, there remains a concern of all colaborators in order to 
perform new trainings or upgrade existing ones. So, for this the company has an annual training 
plan developed in order to fill the potential training gaps and this plan is updated frequently in 
order  to meet the needs. There are, some trainings provided every year, regardless that the 
colaborator already have done it in previous years, such as pharmacovigilance and ICH-GCP 
training. 
During the 9 months of internship, as a collaborator of Eurotrials, in addition to the initial 
training, I had the oportunity to perform another type of trainings that served as a source of 
professional enrichment, such as Eurotrials trainings in declaration of Helsinki, introduction to 
epidemiological research, Law No. 46/2004 clinical trial with the medicines for human use, time 
management, epilepsy, risk management, data protection legislation and handling of patient data, 
clinical analysis, excel, among others. In adition, I also performed, autonomously, several specific 
training for the projects that I was involved and I also performed in the some trainings provided 
directly by some sponsors of the studies in which I was involved. 
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4.3 Project specific activities 
 
In this sub-chapter, it will be described the projects specific activities that should be 
performed in order to properly implement and conduct the observational/non-interventional 
studies. The projects specific activities includes, in a first stage, the correct planning of study 
activities, through a investigational site selection and also selection/invitation of the study team, 
followed by qualification visits and study submissions to health authorities (CNPD and to 
investigational sites, if applicable). After final approval being obtained from the respective 
authorities, the next main activity includes preparation of the study initiation and its 
implementation through the realization of a site visit in order to initiate the study. During the 
study conduction, regular contacts with investigational teams and monitoring/quality control 
visits should be done, and at end phase, a last visit to the investigational site will be performed 
(close-out visit). 
 
4.3.1 Planning and initiation of activities 
Before the beginning of any study it is necessary to go first through various stages including 
the first contact with the future site and research team, collecting documents for study 
submission to the different entities, accompany the process of obtaining all the necessary 
approvals, the communication with the differents stakeholders and the preparation of the official 
initiation of the study. All these stages are of great importance to the continuation of the study 
and will be addressed below, however the stages described are not mandatory to occur with the 
same order that here is described. 
 
4.3.2 Site selection and investigational team selection 
One of the initial steps of the study involves the identification and selection of possible sites 
for the implementation of the Epidemiological and/or Late Phase Research study (investigational 
sites) and the investigational team. This is a very important activity because the success of a study 
also depends, mainly, on a correct selection of investigators. The identification of possible 
investigators should be made considering different sources of information available by the time of 
selection, namely based on sponsor’s suggestion, based on available information about the 
experience of the potential investigator, investigator’s interest regarding the project and his/her 
availability for its conduction/participation. 
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On the other hand, the initial selection of the participating investigational sites may be 
performed by sponsor or by the PM/ CRA of the study, if applicable, taking into account the 
evaluation of important parameters such as: local EC/AB time for approval (when applicable); site 
logistic conditions; availability and human resources; GPP, GEP and/or GCP compliance and 
available population for the study / predicted recruitment rate. However, it is also important to 
note that depending on the type of studies to be implemented, some requirements can be 
different, for example, for an Epidemiological and/or Late Phase Research study where the data is 
obtained by phone or by direct request interview to passer-by people in the open street or 
houses, the main selection objective may be only select representative regions of the country. 
This selection and identification is a responsibility of the sponsor or of the sponsor 
representatives, so the study PM or study CRA can be responsible for identifying and selecting the 
investigators that will participate, if agreed with the sponsor. However, in most studies in which I 
was involved, the selection was always performed by the sponsor and then the monitoring team 
had the responsability of contacting potential investigators, again, to confirm their interest, 
availability and conditions to participate in the study. For this, the study documentation was sent 
to the sites only after the confidentiality agreement had been signed by the study team, in which 
they assumed the commitment to confidentiality regarding to the study information that they 
would have access. Having said that, not only with a view to better inform potential researchers 
but also in order to properly plan the subsequent phases, it is important to present 
documentation and training in the main study, which usually includes the: 
 
 Study Protocol (or synopsis); 
 Case Report Form. 
The CRA/monitoring team should then have training in these documents (or other, if applicable, 
such as scales, pharmacovigilance forms, among others) so that it can transmit crucial information 
and clarify any questions that may arise. 
 
4.3.3 Qualification visit 
Even at the stage of selection of the sites and investigational teams, but after the initial 
selection of the participating sites, qualification visits/calls can be performed to the 
investigational sites in order to better assess the existence of conditions for the development of 
the study and evaluate some issues such as: the site’s facilities, namely human resources, logistic 
issues (for example, the existence of computer equipment in case study provides an electronic 
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CRF), the average time to approval of the applicable entities and recruitment potential of the site 
for implementing the study.  
At the Epidemiology & Late Phase Research department, the qualifications visits are not very 
common, so during the internship, I had no opportunity to participate in this type of visits, 
however all of these points are addressed and discussed remotely (by phone) prior to the 
potential submission of the study to the site. 
 
4.3.4 Submission to CNPD and Local EC/AB 
Although, most of the times, the investigational sites and investigational teams are already 
chosen by the sponsor, the study cannot start prior to obtaining approval by Local EC/AB. In this 
way, it is essential that the documentation of the study (protocol, patient information and 
informed consent form, CRF and other documents in which there might be data collection, such 
as scales, questionnaires, diaries and pharmacovigilance forms) are submitted for review and 
approval of such entities. 
 
4.3.4.1 Submission to the National Authority for Data Protection  
Regarding the submission of non-interventional studies, it is not necessary to submit these 
for evaluation and approval by the National Ethics Committee for Clinical Research (CEIC), whose 
mission is to ensure the protection of the rights, safety and welfare of partcipantes in clinical 
trials, by issuing an ethical opinion about research protocols that are submitted (63) and, by the 
National Authority of Medicines and Health Products (INFARMED), whose main mission is to 
ensure the quality, safety and efficacy of medicines and health products, ensuring the highest 
standards of public health and the consumer protection (64).  However, such as in clinical trials, 
generally, it is necessary that all non-interventional studies are submitted to the Portuguese Data 
Protection Authority (CNPD – Comissão Nacional de Proteção de Dados) since, in most studies, it 
is necessary to collect identificable data of patients6) (18).  Here it should be noted that, although 
being more common, first to perform the CNPD submission, this can also be done in parallel with 
the submission to the investigational site, however the study cannot start prior to obtaining the 
approval of the CNPD. 
Regarding to CNPD submissions and once I followed the initial activities of  some studies, I 
had the opportunity to perform and/or collaborate on some electronic submissions to the CNPD, 
                                                          
6
 It is considered identifiable the person who can be identified directly or indirectly, in particular by 
reference to an identification number or to one or more factors specific to his physical, physiological, 
mental, economic, cultural or social identity. 
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and also to follow-up the process until final approval and also notify the CNPD about the 
occurrence of minor amendments to the study documentation. So, I could learn that the 
notification procedure starts with the preparation of a request for authorization to CNPD. The 
application is submitted totaly electronically, through the completion  of a online form, available 
on  CNPD website. This request must include some information required by CNPD, once the form 
is organized into the following sections:  
 Responsible for treatment;  
 Purpose of treatment (which, in this case, consists of selecting the option "estudos 
clínicos observacionais (não interventivos)");  
 Personal data contained in each record (identification of the type of data processed);  
 Data collection (direct, if data were provided directly by the holders, or indirect 
collection, if data is collected through the physicians);  
 Comunication of data to third parties;  
 Interconnects of treatments; 
 International flows of data to third countries; 
 Deadline for storage of personal data;  
 How is performed the right of data access (in person, writing or other);  
 Measures in order to implement security (physical security measures and logical 
security measures). 
The request also should include the following attachments: patient information and informed 
consent form, CRFs, study scales and the justification of the racial data collection (if applicable), 
and also the payment receipt copy to CNPD. This fee payment receipt copy must be sent to CNPD 
within a maximum period of 3 working days. 
 
4.3.4.2 Investigational site submission 
To initiate a study in a specific site, we will have to obtain the approval of the CNPD but also 
the approval of two entities (if applicable): Local EC and Local AB. For this, we need to prepare 
and submit some essential study documentation such as: 
 Protocol last version and amendments (if applicable); 
 Signature page of the protocol and amendments (if applicable); 
 Patient information and informed consent form and amendments (if applicable); 
 CRF (draft is acceptable) and;  
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 Other documents, if applicable, such as clinical assessment scales, diaries, 
questionnaires, pharmacovigilance forms, among others;  
 Curriculum Vitae (CV) of the investigational team (but at this stage, is usually 
satisfactory for submission only the signed and dated CV of principal investigator); 
 Financial and/or investigational agreements, if applicable; 
 Delegation letter from the sponsor  to the CRO; 
 Authorization from head of departement and even, if applicable, a statement by 
Principal investigator and; 
 The notification or approval of CNPD.  
This process however is not the same for all investigational sites because, for hospital cases 
for example, there are hospitals who demand some specific documentation (namely, EC specific 
forms, AB specific contracts template and statement from Principal Investigator), which requires 
that the monitor/ monitoring team seeking information about the existence of such situations 
and adapt the documentation for study submission for the applicable site. Once submitted, the 
study will be evaluated, at least, by the entities referred above, but this evaluation period may be 
different depending on the hospital, since, among others, there are hospitals with a lower 
frequency of EC/AB meetings for evaluate the submited studies. On the other hand, in the 
evaluation process, the local EC/AB may also emit questions, which can delay the approval 
process of the study in the hospital in which this will occur. However, this “delay" can be 
attenuated if the answer to the questions is celere, what might be possible if there is a 
contribution of the investigational team motivated and available in order to accelerate the study 
authorization in each of the correspondent sites. 
Regarding the hospitals submissions, I had the opportunity to perform many submissions to a 
variety of hospitals (in continental Portugal and also in the Islands). In this way, it was possible for 
me, to verify the existence of specific requirements and procedures in some hospitals and prepare 
all documentation in order to meet such requirements. For example, I could verify that some 
hospitals had investigational departments that centralize submissions therefore, all the 
documentation should be delivered in such investigational department, but I could also verify that 
there were cases in which the study process would have to go towards two differents hospitals 
because the EC and AB of the hospital group was situated in two differents hospitals (EC is 
situated in one hospital and the AB is situated in another hospital), so it is very important to take 
this into account when we prepare the documentation. Additionally, I could understand that 
there are hospitals who demand some specific documentation (EC specific forms, AB specific 
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contracts template and statement from Principal Investigator, among others) and/or only accept 
the submission if there are also delivered of all the documentation in electronic format/CD-ROM.  
After this submissions, for different studies that I have been involved over the past 9 months, 
I also perform, on a regular basis, many contacts with local EC/ AB (mostly with the secretariat of 
the AB) to follow-up the study evaluation process, in order to provide information to the 
monitoring team, sponsor and investigational team, if applicable.  
Still on this topic, it should be noted that even though the study obtains the necessary 
approvals, in the case of amendments, it can be necessary that the study be re-evaluated and be 
given a new approval. 
 
4.3.5 Preparation of the study initiation 
Once obtained the final approvals from the respective entities (EC/ AB/ CNPD) the study is 
finally authorized to be conducted, so for it could realy happen, it is essential to have all 
documentation prepared in order to be possible to distribute for the investigational team so that 
the study may be initiated. In this sense, I have been involved in the collection and preparation of 
all the necessary materials (including preparation and/or collaboration in the PowerPoint 
presentation of the study to be made to the investigational team). The preparation of the study 
initiation also include the preparation of files (Investigator Files) that will be delivered to all sites 
as well as the files that will be in the kept by the CRA, at Eurotrials office, containing essential 
study documentation (Trial Master File). 
The preparation of these files, is also a fundamental task as, in accordance with the existing 
guidelines, the essential documentation of research activities should be securely maintained to 
provide evidence of activities, for example, in the case of a regulatory inspection or an internal or 
external audit (promoted by the sponsor). Here it should be noted that in some studies, the 
documents may have to be sent to a central file (not located at Eurotrials office), but in non-
interventional studies this is not so frequent  because most studies are at a national level.  
During the internship, I prepared, autonomously, these files and I was responsible for 
keeping them organized and updated. So, I had the opportunity to verify that indeed the 
conducting of non-interventional studies also generates a lot of documentation and just how 
important it is to keep it properly filed and updated, especially in studies that involve many sites 
and many investigators. 
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4.3.6 Site initiation 
After all these stages already mentioned above, the next step is to schedule a meeting 
(presentialy or remote) with the study investigators in order to initiate the study because the 
initiation vist can only be performed after the respective approvals have been obtained. 
In the observational/non-interventional studies it is common that the training is given during 
meetings at the investigational site, by phone/web or during a national/regional meeting of 
investigators where all study procedures are explained and all materials are distributed. However, 
regardless of the initiation visit/call  be made for each investigational site or through a national or 
regional meeting, the main objective are the same: ensure that all aspects of the study are 
discussed with the Investigator and other key investigational site team members involved in the 
study (for example, training the site staff in the study protocol; patient information and informed 
consent form; information provided to the patient, safety reporting procedures to follow in the 
event of an AE/SAE, study specific procedures; recruitment period timelines; monitoring 
procedures; co-monitoring visits/calls, audits and inspections and highlighting CRF common errors 
and respective corrections; ensure that all the documentation is ready and archived, and that all 
information and resources are available, so that patient’s inclusion may beginning as of that visit 
date on. During the Initiation Visit/Call, the study personnel will also be trained in study specific 
guidelines and regulatory obligations. 
The beginning of the study is a critical step and it is essential that there is a training and 
capacity the investigational team for the implementation of the study in order to ensure that all 
information and procedures needed, were assimilated by the team in order to a correct start of 
the study. However, and as referred, those visits/calls can only be performed after the applicable 
national regulatory requirements have been fulfilled. For that reason, during preparation of an 
initiation visit/call, the CRA should confirm that all necessary approvals/documents to initiate the 
study are available, namely: 
 Authorization from CNPD; 
 Authorization from applicable local EC and applicable local AB where the study will take 
place;  
 Authorization from head of department (but it will be not mandatory if he/she is 
simultaneously the principal investigator); 
 CV of site staff known to participate in the study by the time of Initiation Visit 
preparation; 
 Signature page of the last version of the protocol, and amendments, if applicable, and 
confidentiality agreement signed by the principal investigator; 
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 Contracts between sponsor/designee and principal investigator/institution, if applicable; 
 Any additional required local documentation, in accordance with specific institution 
regulations; 
 Any other document according with local requirements. 
 
However, depending on the type of studies to be implemented, it may not be necessary 
some approvals/documents to initiate the study. 
These visits are usually conducted by the CRA of the study and sometimes the sponsor is also 
present. From the site it is very important to have all the team members that will be involved in 
the study. The principal investigator, must be present and the greatest possible number of 
elements of the investigational team since during the initiation visit, are discussed important 
topics such as: 
 Protocol presentation; 
 The process for obtaining the informed consent form; 
 Presentation of CRFs and/or study questionnaires; 
 Notification of adverse events (depending on the nature of the study, the approach to this 
topic can be more or less thorough); 
 Explanation that all information collected within the scope of the study, should be 
recorded in the clinical process; 
 Procedures for communicating with the study CRA; 
 Collection of pending documentation, forms and signatures, if applicable. 
 
However, although there are several different methods concerning the presentation of the 
study, the most common procedure is to perform study initiation visits to each site. So,  during my 
internship I was only involved in studies whose initiation visit was performed by CRA at all 
investigational sites, after the applicable national regulatory requirements have been fulfilled. 
Anyway, it is essential that this visit will be very well planned because it may be the first contact 
of the CRA with some of the elements of the investigational team and also may be the first 
contact of these with the protocol. Therefore, it is very important that all procedures are properly 
explained, and understood, and that all the issues are clarified for, after this visit, all the elements 
are able to begin the inclusion of patients. For this, I have verified that the CRA ability to capture 
the attention of the team, becomes a very important issue. 
Following this visit/call and if applicable, the CRA must complete a site initiation visit report 
where are described the items that were discussed during the visit (namely, if study objectives, 
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study protocol, patient information and informed consent form, CRF completion and corrections, 
treatment period and study procedures, serious adverse events/ adverse events reporting and 
follow-up, monitoring procedures, source documents, were or not discussed) the elements 
presents, the issues that eventually were pending (for example obtain a study staff CV, as well as 
others relevant informations namely regarding site personnel motivation, commitment, 
performance and training). Site initiation visit report can be reviewed and discussed with the PM, 
if applicable, and must be sent to sponsor for their knowledge/ review. 
 
4.3.7 Monitoring / Quality control 
During the recruitment phase and/or during the conduction phase of the study, it is essential 
to monitor all performed activities. However, such as in the initiations visits, in observational/non-
interventional studies, is the common existence of different methods for the conduction of such 
monitoring activities. So, these can be made in the investigational site (throught a visit) or can be 
done remotely (by phone contact). Anyway, whenever possible, these must be performed 
particularly with the aim of: 
 Assess the recruitment and continuous patient participation and if they meet the criteria 
of eligibility; 
 Make the quality control of performed activities: 
- To verify the obtention of the informed consent form before collecting any other 
personnal data; 
- To verify the correct fill of the CRFs (identification of discrepancies, errors or 
inconsistent data that must be corrected by the investigator); 
- To verify the correct registration of information in source documents/ to monitor the 
data collected for the study – Source Data Verification (SDV), that is, perform a 
comparison between the CRF and the source data that can be found in source 
documents (medical records, laboratory results, among other documents), to ensure the 
data is accurately captured in the CRF; 
- To verify the compliance with applicable law. 
 Assess if the pharmacovigilance procedures are being fulfilled; 
 Verify if only are participating in the study, the qualified/trained elements, whose 
activities in the study were authorized by the principal investigator; 
 Collection of CRFs, in case of the same are in paper format; 
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 Update the investigator file according to the applicable SOPs; 
 Motivate the investigational team; 
 Evaluate and resolve the potential difficulties of the team; 
 Assess whether the pending actions resulting from the last visit were resolved and, if 
not, perform the follow-up until they are resolved. 
So, the main objective of these visits/calls is also oversee the study progress, and to ensure that is 
conducted, recorded, and reported in accordance with the protocol and also in accordance with 
the ethical principles laid down in the Declaration of Helsinki, according to GPP, GEP, and/or GCP 
and also applicable local regulatory requirements and laws. After these visits, and depending on 
the study and sponsor, will also be performed a visit report which describes the items that were 
discussed during the visit and potential discrepancies detected, the study team elements that 
were present, the issues that eventually remained outstanding and those that were resolved, as 
well as other relevant information. 
Despite the importance of all these activities, it is possible to understand that, if the 
monitoring activities are done remotely, it will be more difficult to verify some of the aspects 
previously mentioned. In the same way, although it is carried out a monitoring visit to the 
investigational site, may be some pending situations whose resolution may have to be carried out 
remotely but very often, this visits are extremely important. So, the existence, or not, of face-to-
face visits will be determined by the study sponsor and may even be more than a monitoring visit 
to each site, according with what is stipulated in advance by the sponsor. It should also be noted 
that, in studies in which is not predicted the existance of on-site monitoring visits, throughout the 
study, is sometimes agreed the possibility to perform quality control visits of the data generated 
at the end of the study or during the study to a sample of the investigational sites, randomly 
selected. The quality control visits have the purpose to verify all patient data included, in order to 
assess the quality of the recorded information on the CRF in comparison with the various source 
documents (clinical process; laboratory results; questionnaire of QoL; patient diary, as applicable). 
In the case of a selected site, the records of clinical processes for validation of information should 
be available. 
In contrast to the described in the section of the initiation visits, with regards to monitoring 
activities, I had the opportunity to participate actively in a quality control visit where I performed 
some of the activities mentioned with a special focus, as expected, at the point on the control of 
quality of activities (namely, assess if patients meet the criteria of eligibility and verify the 
obtention of the informed consent form before collecting any other personnal data, the correct 
fill of CRFs, the correct registration of information in source documents and if only are 
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participating in the study the qualified/trained elements whose activities in the study were 
authorized by the principal investigator; assess if the pharmacovigilance procedures are being 
followed and update the Investigator File according to the applicable SOPs). During these 9 
months, I was also involved in several in-house monitoring activities such as: support in the 
preparation of monitoring visits; verification of the correct completion of CRFs on paper format 
and later queries emission well as the follow-up to the resolution; contact with electronic CRFs 
and verification of some data inserted; quality control of documents contained in the Trial Master 
File Site Doc and sending of missing documents and materials required for the recruitment 
continuation and to the follow-up of patients. I also participated actively in the processing of 
payments to investigational sites; in preparation of pocket guides for investigators, newsletters 
and other tools for a better study management and monitoring.  
 
4.3.8 Close-out the investigational sites/ study close out 
Close-out visit should be the last visit of the study to the investigational site with the 
objective of ensure the adequate completion of the study procedures at that site and to make 
sure that the Investigator understands his/her continuing obligations.  
This visit or call should be performed when the study is concluded (at the site or remotely), in 
accordance with protocol but also when sponsor decides to interrupt the study in a single or all 
the investigational sites and/or when the Investigator, EC, health authorities or AB, if applicable, 
request the interruption of the study or the investigational site participation in the study.   
The contact made with each participating investigational site, in order to be officially close 
the site, may be through a visit, by phone or can simply be done through a notification letter, 
depending on the study and the previously defined by the sponsor. During the closing process a 
retrospective analysis of the relevant aspects of the study in general, and of the site in particular, 
should be made, including the total patients recruitment achieved, the investigator fees already 
received or to be received by the site (if applicable), and the period of the study documentation 
retention and archive conditions. Regarding this last point about the archive period and 
conditions, due to the fact that currently there is no legal standard regulamentation for 
observational studies, these deadlines are normally based on guidelines followed in each project, 
of which are example the GPP, which indicates that the data collected during an 
observational/epidemiological study must be preserved for a period not less than 5 years after 
the first publication of the results (after final report or first publication of study results, whichever 
comes later) (25). All the study documents, such as: study protocol and all approved amendments; 
a final report of the study; all source data; documentation adequate to identify and locate all 
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computer programs and statistical procedures used; copies of electronic versions of analytic data 
sets and programs, computer printouts, if feasible; correspondence pertaining to the study, SOPs, 
patient information and informed consent releases, copies of all relevant representative material, 
copies of signed institutional review board and other external reviewer reports, and copies of all 
quality assurance reports and audits, as applicable, should be kept in a safe place and with 
restricted access (25). Additionally, the study sponsor may indicate, periods of archive data, 
higher than the established by the above guidelines.  
Depending on the type of the study, the CRA must ensure that the regulatory authorities and 
the local ECs are notified of the completation/ premature ending of the study and follow the local 
legislation regarding the specific procedures and timelines for any of these notifications to be 
performed (if applicable). 
During my intership I followed, essentially, observational/non-interventional studies that 
were in the early stages, I had no opportunity to attend on any close-out visit. However, I have 
been involved in close out activities, namely in the process of following the resolution of 
outstanding queries, in order to later transfer CRFs for Data Management department of 
Eurotrials and, I also helped in sending letters to the hospitals AB/EC and to the investigational 
team, in order to notify the study termination. Additionally I also observed the procedure relating 
to a international study whose activities were premature ended by the sponsor decision. 
 
4.4 Others activities performed 
 
Even during the internship, I have been involved in some activities related to the company's 
quality assurance procedures.  
An audit is a systematic and independent examination of the activities and documents 
related to a clinical study, which is performed to determine whether the activities were properly 
conducted and whether the data were registered, analyzed and reported with total accuracy, in 
accordance with the protocol, sponsor’s SOPs, with good clinical practices and applicable 
regulatory requirement(s) (12). Therefore, there may be two types of audits: internal or external. 
Internal audits are conducted by the company, according to the quality system implemented by 
the same, in order to ensure the quality of the studies conducted by the company's team. On the 
other hand, external audits are carried out by the initiative of study sponsors or by quality 
entities, of which, Eurotrials has obtained a certification (ISO certification, for example). 
In this sense, I had the opportunity to be involved in the preparation of an internal audit that 
would be carried out in accordance with the internal quality standards of Eurotrials. This activity 
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was very important because it allowed me to understand closely how important is to have the 
documentation of the study properly filed, as well as to have the tools to facilitate the 
organization of the same. Moreover, once the Eurotrials is certified under ISO 9001:2008, during 
the internship period, I accompanied the ISO surveillance audit that occurred. Although, in this 
audit, the activities performed have been few, this allowed me to see that the main focus of this 
audit is distinct from those previously mentioned, since the ISO auditor wants to ensure, 
essentially, that ISO standards are followed and that the company continues to develop its 
activities with a view to improving the quality of them. 
Finally, I also participated in some activities of the review company's SOPs by writing a draft 
of a new SOP for the Epidemiology & Late Phase Research department, so these activities were 
also allowed me to enrich my internship. 
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5. Discussion 
 
The 9 months of internship provided a very enriching experience, both professionally and at 
personal level. Throughout these months, I could enhance the knowledge acquired during the 
master's degree in Pharmaceutical Biomedicine as well as acquire new knowledge, even because 
the previously acquired knowledge in master’s degree was more directed to the interventional 
studies. Nevertheless, during this period I could put into practice many theoretical knowledge 
obtained during the first year of the master’s degree so, I think that, it was an great tool to 
prepare me better for the working world. 
In addition to the support obtained by the afore mentioned training, I could not fail to 
mention the importance of all elements of the Epidemiology & Late Phase Research department, 
who contributed much to the success of this internship, once they sought to integrated me in the 
ongoing projects, was always available to accompany me and clarify doubts and, was given me 
the opportunity to develop the aforementioned skills and helped me identify some weak points, 
in order to try to improve them. Moreover, was possible to verify that this environment of mutual 
help is not exclusive of the department where I was integrated because, in Eurotrials, there is a 
very good working environment, with equally good interaction between collaborators of different 
departments. 
Regarding of the activities performed, during these 9 months, and unlike of what happened 
in the previous year where the company has received colleagues of master degree and has 
provided to them a multidisciplinary experience, this year I was only involved in activities 
performed by the Epidemiology & Late Phase Research department. However, I don’t think that 
this was a negative aspect because I performed diversified activities and I could deepen, even 
further, the knowledge in the tasks performed in this department so, this internship prepared me 
very well to perform future tasks more independently. Still, although the activities performed are 
only under the scope of Epidemiology & Late Phase Research department, it was be possible to 
interact with other Eurotrials departments, because as CRA Late Phase in training, I performed 
some activities in articulation with other departments, namely with the Data Management Unit, 
such as transfer the CRFs for Data Management Unit and monitoring the queries emitted for 
them, after introducing the data in the databases. I also performed some activities in articulation 
with the Finance and Administration department under the management activities of the 
payments to be made to the centers and Investigators (where applicable); with the department of 
Clinical Trials whenever it was necessary to have information sharing, and even with the Quality 
department in activities related the audits preparation, when I had questions regarding quality 
procedures, and when I was involved in the activities of revision of the company's SOPs. This 
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interaction helped me to understand the importance of the interaction between different 
departments and the team work, in order to have studies well designed and successfully 
implemented and conducted. 
As regards the perception taken along the performed activities, I have confirmed the 
challenge to be CRA since, the CRA plays a central role in the communication at all levels, not only 
with research teams but also with sponsor. The CRA has also the responsibility to ensure the 
proper conduct of the studies and therefore have to adapt to different requirements, different 
"publics", different stakeholders and studies very diversified in order to perform the function in 
the best way. In this sense, this experience also contributed to a better perception of the type of 
activities performed by a CRA and the challenges faced, particularly in the area of non-
interventional studies. 
Indeed, all activities described in section 4 – Ongoing studies and developed activities, have 
helped me to deepen my knowledge regarding to the conduct of observational/non-
interventional studies and acquire new skills. By analyzing my internship, I recognize the 
importance of the start of the activities that I have  described in section 4.2.2.1 – General training 
program, with general training in the company SOPs, the collaborator manual and other reference 
documents (GPP, GEP, Helsinki Declaration, ICH-GCP, local legislation, among others), because 
these trainings constitute a first tool, not only to the integration of the new collaborator but also 
to serve as a basis for the activities that will be performed later, since they will have to follow the 
existing legislation and/or reference documents and procedures adopted.  
Regarding to the performed activities, the activity that where I was mostly involved was in 
preparation of submissions processes to the health authorities and subsequent follow-up of the 
evaluation of studies as well as in the preparation of material for the visits to the centres and in 
the management of the archive of the documentation generated during the study.  
Regarding the studies submission activities, I can say that these contributed to understand the 
existing regulatory requirements and the differences that may exist, not only from type of 
centres, differences between sites, but also the differences depending the type of study to be 
implemented. By follow the submission activities, I also developed some skills including the 
communication skills with different stakeholders (EC/ AB, Investigators, sponsors). I could also 
verify that, in addition to differences exist in study submissions between different types of sites, 
there are also differences between sites of the same type, in the case of hospitals, for example, 
even if the same study is submitted for the same entities of each hospital, the approval times can 
be very different and can also be requested different documents and procedures. Still on the 
submissions, I realized how bureaucratic and slow can be to implement a study. 
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The other activities developed in-house also showed me how important are to have the 
documentation correctly archived, develop good monitoring tools (such as trackers related to the 
study evolution) and, preparing and report all the visits performed to the investigational sites. As 
regards to the investigational site and team, I also could understand that is not always easy to 
contact all the team and keep everyone motivated. This also happens because, although the 
observational/non-interventional studies are conducted during, and in accordance with, the 
clinical practice, many times, the investigators has no the availability that we would like. However, 
during this internship, it was possible to verify that, if the investigational team is motivated for the 
study, they will be more receptive and more available for contact with the monitoring team and, 
the study will be better conducted, so it is essential to be able to maintain the communication 
with team. In the same way, I verified the added value that is the integration of study 
coordinators, on the investigational teams, because it is an element more available and that can 
centralize the information from other team members. 
During this internship as CRA Late Phase in trainee, I could contact with different types of 
protocols of different types of studies (around 15 study protocols, in several therapeutic areas - 
see Appendix B - Main studies ongoing during the internship), with different requirements and 
different designs and objectives, in different sites and, from different sponsors. Thus, I believe 
that this opportunity to be involved in many different studies, at all levels, and with different 
sponsors is a great advantage of being a monitors in a CRO. But, I must confess that initially it was 
difficult from me to disconnect from the requirements of clinical trials, because the first year of 
master’s degree was more focused on clinical trials and, in the clinical trials, the procedures are 
more specific and better defined. The non-interventional studies (or late phase studies - studies 
with market drugs) have more procedures than the epidemiological studies (population based 
studies), and can allow the evaluation of  large numbers of patients/consumers, document the 
actual clinical practice, allow heighten disease awareness, support research and scientific inquiry, 
cultivate key customer relationships and, generally are less expensive than clinical trials but, the 
regulatory submissions of them, can vary from country to country since the need to perform a full 
submission until perform a simple notification because there isn´t a harmonized legal framework 
for this kind of studies (65). While the supplements regulations and guidelines for non-
interventional studies rapidly being changed and are far from being harmonized in the EU, it is 
necessary that the study stakeholders check with local authorities and/or ethics committee 
before starting non-interventional studies (65). This point was an difficulty detected during the 
internship because there is no harmonization of criteria for the studies evaluating from different 
local entities, which leads to studies that can be approved in some investigational sites, has be 
disapproved in others. Moreover, some local ECs when performing the studies evaluation have 
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different criteria in considering the same study has interventional or non-interventional. In this 
sense, I think it would be really very important to have a standardization of evaluation criteria. 
Throughout this period was also important to verify the procedures regarding the 
retrospectives studies. Here although all the information can be extracted from the patient 
clinical process, I have verified that, similarly, it is expected that the patient go to a consultation, 
according with normal clinical practice, and is obtained his informed consent before being 
collected any data. 
During these 9 months, I had the opportunity to work with different monitors (inclusively 
seniors) and everyone contributed, over the time, to make me more independent, and apt to 
correctly perform the activities with minimal supervision. 
Throughout these months I increased the interest for this area and this experience allowed 
me to better understand the essential role of CRA and CROs in health research. It also gave me 
practical knowledge on how to properly submit, conduct, report, monitor and close-out the 
observational/non-interventional studies. 
During my internship, what I enjoyed the most was the opportunity to meet so many studies 
with different regulatory requirements, be actively integrated in these studies. In the same way, I 
enjoyed to perform the activities described in the Chapter 4 - Ongoing studies and developed 
activities and the possibility to directly contact with so many different stakeholders. On the other 
hand, I did not had the opportunity  to attend to a close-out visit and would like to had the 
opportunity to perform more visits to the investigational sites because I think it is, really very 
important to the CRA in training. However, at the end of the internship period I was invited, by 
Eurotrials, to assume the role of CRA of Epidemiology & Late Phase Research department. This 
invitation was very positive and will allow me, in the near future, the opportunity to improve my 
skills and to perform other tasks and more autonomously. 
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6. Conclusion 
 
This report aimed to present the activities performed during the 9 months of internship in a 
Portuguese CRO, Eurotrials, Scientific Consultants, a company which provides services in the field 
of clinical research and specifically describing the activities of monitoring observational studies / 
non-interventional, developed during the internship, as well as the skills acquired. 
The main objective of this internship was promote a "bridge” between the knowledge 
acquired during the first year of the master’s degree, and the labour market and also serve as a 
source of new knowledge and prepare myself, to work in monitoring area. 
Now I can conclude that the master’s degree was an important tool to provide the basis for 
working in any of the related areas of clinical research and, particularly, for monitoring area. After 
these 9 months, I can also conclude that the internship allowed me to participate in different 
projects and give me a wide range of learning opportunities. So, not only allowed me to put into 
practice the knowledge acquired during the master's degree but also acquire new knowledge that 
prepared me to ingress in the working world. Throughout this period, I also acquire very clear 
notions of what are the functions of a Late Phase monitor and its role in the research studies.  
For all of this and, in conclusion, according to established objectives, I can say that they were 
completely achieved. 
In the near future, I would like to continue to work in this area and continue improve my 
skills and knowledge to be able to carry out any activity successfully and autonomously. 
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Appendix A - Glossary 
 
Glossary 
 
CNPD (Comissão Nacional de Protecção de Dados) - Portuguese Data Protection Authority. The 
CNPD is an independent body, with powers of authority throughout national territory. It is 
endowed with the power to supervise and monitor compliance with the laws and regulations in 
the area of personal data protection, with strict respect for human rights and the fundamental 
freedoms and guarantees enshrined in the Constitution and the law (66).  
 
Contract Research Organization (CRO) - A CRO can be described as an organization that is 
contracted by a sponsor to manage various steps in the drug development process, including 
conduct of preclinical studies, clinical study design and execution, data management, analysis, 
medical writing, and regulatory submission (67). 
 
Epidemiological study - Any epidemiological investigation intends to study in human subjects the 
distribution and determinants of disease (38). 
 
Good Clinical Practices – A standard, internationally recognized, for the design, conduct, 
performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that 
provides assurance that the data and reported results are credible and accurate, and that the 
rights, integrity, and confidentiality of trial subjects are protected (12). 
 
Informed Consent – “A process by which a subject voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the trial that are 
relevant to the subject's decision to participate. Informed consent is documented by means of a 
written, signed and dated informed consent form” (12). 
 
International Conference of Harmonization - Standardized norms followed by Europe, Japan and 
United States in order to facilitate the mutual acceptance of clinical data by the regulatory 
authorities in these jurisdictions (68). 
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Pharmacoepidemiology - Is the scientific backbone of therapeutic risk management the process 
of assessing a product's benefits and risks, and developing, implementing, and evaluating 
strategies to enhance the overall balance of such benefits and risks (25). 
 
Pharmacoeconomic study - “A pharmacoeconomic study evaluates the cost (expressed in 
monetary terms) and effects (expressed in terms of monetary value, efficacy or enhanced quality 
of life) of a pharmaceutical product. Pharmacoeconomic studies serve to guide optimal healthcare 
resource allocation, in a standardized and scientifically grounded manner” (69). 
 
Pharmacovigilance - “The science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem” (70). 
 
Post-Authorization study - “Any study conducted with a medicinal product authorized in the 
European Economic Area” (71). 
 
Primary Healthcare Centres - Public health services with administrative autonomy, consisting of 
several functional units (Unidades de Saúde Familiares, Unidades de Cuidados de Saúde 
Personalizados, Unidades de Cuidados na Comunidade, Unidades de Saúde Pública, Unidades de 
Recursos Assistenciais Partilhados) (72). 
 
Qualification visit/call: Evaluation of investigator/team and site capabilities namely regarding 
human resources, equipment, logistical issues and recruitment potential for implementing the 
study (72). 
 
Sponsor - A person who takes responsibility for and initiates a clinical investigation. The sponsor 
may be an individual or pharmaceutical company, governmental agency, academic institution, 
private organization, or other organization (73). 
 
Standard Operating Procedures - Detailed, written instructions to achieve uniformity of the 
performance of a specific function (72). 
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Appendix B – Main studies ongoing during the internship 
 
Therapeutic area  Study description 
Neurology  National, non-interventional, multicentric study in the area of 
Epilepsy. 
Infecciology  National, observational, post authorization safety study, 
retrospective and prospective, multicentric study in the Human 
Imunodeficiency Virus area. 
Lysosomal storage diseases  International, observational, cross-sectional and retrospective, 
multicentric study in the Niemann-Pick type C disease. 
Premature Ejaculation  International, non-interventional prospective post-approval safety 
study in patients with premature ejaculation. 
Endocrinology  International, non-interventional post authorization safety study 
with patients with Diabetes mellitus type 2. 
Haematology  International non-interventional post authorization safety study 
with patients with multiple myeloma. 
Reumathology  National, observational, prospective, parallel group study in 
Rheumatoid Arthritis and Axial Spondyloarthritis. 
Pain  National, observational, multicentric study in the area of Chronic 
Pain. 
Psychiatric and Neurology  National, observational, prospective, multicentric study in the 
Alzheimer disease.  
Psychiatric  National, observational, cross-sectional, multicentric study in the 
Schizophrenia disease. 
Oncology  National, observational, multicentric study in the area of Renal Cell 
Carcinoma. 
Endocrinology  National, observational, multicentre study in the area of Diabetes 
mellitus type 2. 
Cardiology  National epidemiological study to evaluate the prevalence of 
Hypertension and salt intake. 
Infecciology  National epidemiological study to evaluate the national situation of 
chronic hepatitis B. 
Osteoarthritis  National, epidemiological study, observational, cross-sectional to 
evaluate the prevalence of osteoarthritis. 
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